Business
Appointment of adviser
Appointment of adviser.
About this update from Immupharma Plc
[{"type":"text","content":"\n Immupharma PLC\n15 February 2007\n\n\nFor Immediate Release 15 February 2007\n\n\n ImmuPharma plc\n\n Appointment of adviser\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug\ndiscovery and development company ImmuPharma plc is pleased to announce the\nappointment of Teather & Greenwood Limited as nominated adviser and broker. The\nappointment is with immediate effect.\n\nDawnay, Day Corporate Finance Limited continues to act for ImmuPharma plc as\njoint financial adviser.\n\nFor further information please contact:\n\nImmuPharma PLC:\nRichard Warr, Chairman + 44 20 7152 4080\nDimitri Dimitriou, Chief Executive\nOfficer\n\nBuchanan Communications + 44 20 7466 5000\nLisa Baderoon / Rebecca Skye\nDietrich\n\nNotes to Editors:\nAbout ImmuPharma\n\nImmuPharma PLC is a drug discovery and development company headquartered in\nLondon, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has\nresearch operations in France (ImmuPharma (France) SA) and Switzerland\n(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,\nlargely based on peptide therapeutics, to treat serious medical conditions such\nas autoimmune diseases characterised by:\n\n\n* blockbuster potential in niche markets\n\n* low promotional costs in few specialised physicians and centres and\n\n* lower risk of drug development and lower development costs\n\n\nImmuPharma is a currently developing drug candidates for three different medical\nconditions, each of which would represent a significant breakthrough in its\nfield. The furthest advanced drug candidate targets Lupus, a disease for which\nthere is currently no cure or specific treatment. The other two address moderate\nto severe pain (such as that experienced by cancer sufferers and post-operative\npatients), and MRSA and similar severe hospital-acquired resistant infections.\n\n\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length":2317,"tagName":"div"}]